Spots Global Cancer Trial Database for Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)
Official Title: Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial): A Randomized Phase II Trial
Study ID: NCT02756793
Conditions
Study Description
Brief Summary: A multicenter randomized phase II trial of stereotactic body radiotherapy for oligo-progressive metastatic cancers. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiotherapy (SABR) to all sites of oligo-progressive lesions.Radiotherapy will be administered as soon as possible following randomization, and subjects will be followed until next disease progression. The primary outcome is progression-free survival (PFS).
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Alberta Health Services-Cross Cancer Institute, Edmonton, Alberta, Canada
BC Cancer - Prince George, Prince George, British Columbia, Canada
BC Cancer Fraser Valley Centre, Surrey, British Columbia, Canada
BC Cancer Agency Branch, Vancouver, British Columbia, Canada
BC Cancer - Victoria Centre, Victoria, British Columbia, Canada
London Regional Cancer Program, London, Ontario, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
